Zinc(II) Binding Site to the Amyloid‑β Peptide: Insights from Spectroscopic Studies with a Wide Series of Modified Peptides

• Published in: Inorganic chemistry 2016-10, Vol.55 (20), p.10499-10509
• Main Authors: Alies, Bruno, Conte-Daban, Amandine, Sayen, Stéphanie, Collin, Fabrice, Kieffer, Isabelle, Guillon, Emmanuel, Faller, Peter, Hureau, Christelle
• Format: Article
• Language: English
• Subjects: Amyloid beta-Peptides - chemistry; Binding Sites; Chemical Sciences; Coordination chemistry; Histidine - chemistry; Hydrogen-Ion Concentration; Proton Magnetic Resonance Spectroscopy; X-Ray Absorption Spectroscopy; Zinc - chemistry
• ISSN: 0020-1669; 1520-510X
• DOI: 10.1021/acs.inorgchem.6b01733

The Zn­(II) ion has been linked to Alzheimer’s disease (AD) due to its ability to modulate the aggregating properties of the amyloid-β (Aβ) peptide, where Aβ aggregation is a central event in the etiology of the disease. Delineating Zn­(II) binding properties to Aβ is thus a prerequisite to better grasp its potential role in AD. Because of (i) the flexibility of the Aβ peptide, (ii) the multiplicity of anchoring sites, and (iii) the silent nature of the Zn­(II) ion in most classical spectroscopies, this is a difficult task. To overcome these difficulties, we have investigated the impact of peptide alterations (mutations, N-terminal acetylation) on the Zn­(Aβ) X-ray absorption spectroscopy fingerprint and on the Zn­(II)-induced modifications of the Aβ peptides’ NMR signatures. We propose a tetrahedrally bound Zn­(II) ion, in which the coordination sphere is made by two His residues and two carboxylate side chains. Equilibria between equivalent ligands for one Zn­(II) binding position have also been observed, the predominant site being made by the side chains of His6, His13 or His14, Glu11, and Asp1 or Glu3 or Asp7, with a slight preference for Asp1.